Kiniksa Pharmaceuticals International, plc: Fiscal Year 2025 Annual Report Summary

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has unveiled its annual report for the fiscal year ended December 31, 2025. This summary offers investors a concise overview of the company's operations, financial performance, strategic initiatives, and key risks, highlighting its progress in developing treatments for autoimmune and inflammatory diseases.

Business Overview

Kiniksa is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and bringing to market new treatments for patients with debilitating autoimmune and inflammatory diseases. With headquarters in London, UK, and major operations in Lexington, MA, USA, along with other international sites in Switzerland and Bermuda, Kiniksa takes a global approach to drug development. The company's strategy targets significant unmet medical needs with specialized therapies.

Product Pipeline & Development Status

Kiniksa's pipeline includes several key product candidates, each designed to treat specific autoimmune and inflammatory conditions:

• Vixarelimab: A specialized antibody designed to block a protein target called oncostatin M receptor beta (OSMRβ). It is currently in Phase 2b clinical trials for prurigo nodularis and other chronic itching conditions.
• Arcalyst (Rilonacept): This drug blocks interleukin-1 (IL-1) – a key inflammatory protein – and is a cornerstone program. Arcalyst is already approved in the U.S. for recurrent pericarditis and is being explored for other inflammatory conditions.
• Mavrilimumab: Another specialized antibody, Mavrilimumab targets granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSFRα). It is in Phase 2 clinical development for giant cell arteritis and other inflammatory diseases.
• KPL387, KPL1161, and Abiprubart: These represent earlier-stage programs or preclinical candidates, demonstrating Kiniksa's commitment to expanding its pipeline in autoimmune and inflammatory disorders.

Strategic Partnerships & Collaborations

Kiniksa forms strategic alliances to advance its pipeline and commercial efforts, tapping into external expertise and resources:

• Regeneron Pharmaceuticals Inc.: Collaborates on clinical supply and potential regulatory milestones, supporting the development of specific pipeline assets.
• MedImmune Limited: Holds a license agreement, granting rights to specific compounds or technologies.
• Biogen MA Inc.: Acquired specific assets or programs through an asset purchase agreement.
• Beth Israel Deaconess Medical Center Inc.: Secured a license agreement, potentially providing access to foundational research or intellectual property. These partnerships accelerate development, share costs, and expand market reach.

Financial Performance

• Revenue: In fiscal year 2025, Kiniksa generated revenue primarily from Arcalyst product sales and collaboration agreements, reflecting its early commercialization and strategic partnerships.
• Net Loss: As a clinical-stage biopharmaceutical company, Kiniksa continued to invest heavily in research and development. This resulted in a net loss for the fiscal year, consistent with its growth phase and pipeline advancement.
• Research & Development (R&D) Expenses: The company made substantial R&D investments to advance its pipeline, particularly Vixarelimab and Mavrilimumab, demonstrating its commitment to innovation.
• Selling, General & Administrative (SG&A) Expenses: These expenses supported Arcalyst's commercial activities and general corporate operations.

Financial Health and Capital Resources

Kiniksa's financial health relies on its cash and equivalents, which provide the funding for ongoing operations and pipeline development. At year-end, Kiniksa maintained a solid cash and equivalents position. The company's capital structure includes its equity and any outstanding debt or credit facilities. The company funds its significant research and development and commercialization efforts through a combination of product sales, collaboration revenues, and access to capital markets for potential future equity or debt financing.

Key Risk Factors

Investing in Kiniksa carries inherent risks, typical of the biopharmaceutical industry. Key risks include:

• Clinical Development Risk: The success of product candidates like Vixarelimab and Mavrilimumab faces uncertainties from clinical trials, regulatory approvals, and potential delays or failures.
• Commercialization Risk: Successfully commercializing approved products, such as Arcalyst, depends on market acceptance, competition, pricing, and reimbursement.
• Regulatory Risk: Obtaining and maintaining regulatory approvals from agencies like the FDA proves complex, lengthy, and uncertain.
• Intellectual Property Risk: Protecting proprietary technology and defending against infringement claims critically impacts the company's long-term success.
• Financial Risk: The company's ability to fund operations and pipeline development relies on future financing, which may not always be available on favorable terms.
• Competition: The biopharmaceutical market is highly competitive, with many companies developing treatments for similar indications.

Future Outlook

Kiniksa's strategic outlook focuses on advancing its late-stage clinical programs, expanding Arcalyst's commercial reach, and exploring new therapeutic opportunities within autoimmune and inflammatory diseases. The company aims to leverage its scientific expertise and strategic partnerships to bring innovative medicines to patients and drive long-term shareholder value.

Competitive Position

The biopharmaceutical industry is highly competitive. Kiniksa operates in therapeutic areas with significant unmet medical needs, but also faces intense competition. Several factors influence its competitive position, including the efficacy, safety, and differentiation of its product candidates (e.g., Vixarelimab, Mavrilimumab) and approved product (Arcalyst) compared to existing treatments and therapies competitors develop. Key competitors include established pharmaceutical companies and other biotechnology firms with greater financial, technical, and human resources. Kiniksa's ability to compete effectively depends on its intellectual property portfolio, scientific expertise, the speed and success of its clinical development programs, commercialization capabilities, and its ability to secure market access and favorable reimbursement for its products. The company faces competition across the discovery, development, manufacturing, and commercialization of its products.

Corporate Governance & Structure

The SEC recognizes Kiniksa as a "well-known seasoned issuer" and a "Large Accelerated Filer," designations that indicate a strong track record of timely and transparent financial reporting. The company confirmed its internal controls over financial reporting are effective. As of February 20, 2026, Kiniksa had 76,535,377 ordinary shares outstanding, including Class A, Class B, Class A1, and Class B1 shares. This multi-class share structure may imply differentiated voting rights or ownership interests. As of June 30, 2025, its publicly traded shares (public float) had a market value of approximately $1.114 billion.